Autopsy report · NCT00753740

Efficacy Study of Maintenance IT-101 Therapy for Ovarian Cancer Patients.

“Poor trial recruitment”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 2

Sponsor

NewLink Genetics Corporation

Sponsor type

Industry

Conditions

Cancer; Ovarian Cancer; Solid Tumor

Interventions

IT-101 (12mg/m2/dose); IT-101 (15mg/m2/dose); 5% Dextrose (Placebo)

Participants

0

Sites

7

Countries

United States

Trials that died the same way

• Efficacy and Safety Evaluation for the Treatment of Asthma and Allergic Rhinitis/Rhinoconjunctivitis
  “Due to the low recruitment rate since the start of the trial” (83% match in meaning)
• Myloablative Cord Blood Transplant in Haematological Malignancies (MAC UCBT)
  “Trial closed early due to poor recruitment” (83% match in meaning)
• Intravenous Acetaminophen as Adjuvant Therapy for Pain Control in Geriatric Hip Fracture Patients
  “Difficulty in recruiting subjects for the trial.” (79% match in meaning)
• Effects of Inhaled Treprostinil Sodium for the Treatment of Pulmonary Hypertension Associated With Idiopathic Pulmonary Fibrosis
  “Lack of enrollment to the trial. Very difficult population to recruit.” (76% match in meaning)
• Imatinib for Cytomegalovirus Prophylaxis and Treatment After Allogeneic Hematopoietic Stem Cell Transplantation
  “The trial is terminated due to the extremely low recruitment rate.” (75% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.